Business
Medovex Corporation Updates Name Change and Full Rebranding to H-CYTE
Medovex Corporation Updates Name Change and Full Rebranding to H-CYTE.
About this update from Innoveren Scientific Inc.
[{"type":"text","content":"\nTAMPA, Fla., July 01, 2019 (GLOBE NEWSWIRE) -- Medovex Corp. (OTCQB: MDVX), today updated investors on its name change and rebranding to H-CYTE. The announcement underscores the Company's broader commitment focusing on delivering regenerative anti-inflammatory solutions to treat the unmet needs of patients, as well as bringing new health care solutions to patients domestically and internationally with a focus on improving quality of life, especially for those with chronic diseases.\n In addition to the name and anticipated symbol change, the Company will launch a new corporate website and social channels to provide educational resources for patients. The name change and an accompanying ticker symbol remain subject to the approval of the Financial Industry Regulatory Authority (FINRA). Until that date, the Company’s stock will continue to trade under the existing “MDVX” ticker symbol. H-CYTE CEO Bill Horne stated, “2019 has already been a critical year for our organization. Year to date, we have announced the successful asset purchase of Regenerative Medicine Solutions LLC, established a world-class management team with a documented track record of success, appointed numerous trusted industry veterans to our board of directors and secured financing to continue to execute our business plan. Most recently, we entered into a long-term agreement with Rion that allows us to develop proprietary biologics where we intend to pursue submission of an investigational new drug (IND) application for review by the U.S. Food and Drug Administration (FDA) for treatment of COPD.” Horne concluded, “Today’s announcement of the strategic rebranding to H-CYTE is another important step as our organization continues to evolve. As traditional health care limitations are continually overcome with medical breakthroughs, H-CYTE aims to make those solutions accessible to all patients, especially those who seek the latest in available treatments for chronic conditions that hinder their quality of life.” About H-CYTE Corporation H-CYTE was formed to build and develop a diversified portfolio of innovative medical technology products and services to improve quality of life for patients. The DenerveX® System is H-CYTE’s first product and is intended to provide long-lasting relief from pain associated w...